Research programme: monoclonal antibodies - Cipla Biotech

Drug Profile

Research programme: monoclonal antibodies - Cipla Biotech

Alternative Names: CBT-127; CBT-128

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Cipla BioTec
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Wet age-related macular degeneration
  • Research Breast cancer

Most Recent Events

  • 29 Aug 2016 Preclinical trials in Wet age-related macular degeneration in India (Parenteral) before August 2016
  • 29 Aug 2016 Early research in Breast cancer in India (Parenteral), before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top